Induction of apoptosis in B-cell lymphoma lines
| Cell line . | Origin . | Relative expression of CD23* . | Apoptosis (%)† . |
|---|---|---|---|
| SKW6.4 | Burkitt lymphoma | 100 | 60 |
| SB | Acute lymphoblastic leukemia | 100 | 42 |
| DHL-4 | Diffuse histiocytic lymphoma | 0 | 0 |
| Daudi | Burkitt lymphoma | 0 | 0 |
| Raji | Burkitt lymphoma | 10 | 0 |
| Ramos | Burkitt lymphoma | 0 | 0 |
| Cell line . | Origin . | Relative expression of CD23* . | Apoptosis (%)† . |
|---|---|---|---|
| SKW6.4 | Burkitt lymphoma | 100 | 60 |
| SB | Acute lymphoblastic leukemia | 100 | 42 |
| DHL-4 | Diffuse histiocytic lymphoma | 0 | 0 |
| Daudi | Burkitt lymphoma | 0 | 0 |
| Raji | Burkitt lymphoma | 10 | 0 |
| Ramos | Burkitt lymphoma | 0 | 0 |
The expression of CD23 was evaluated by flow cytometry using phycoerythrin–anti-CD23 antibody. The relative fluorescence intensity (RFI) of antibody binding was determined by comparing the mean fluorescence intensity of phycoerythrin–anti-CD23 antibody binding to cells to that of the mean fluorescence intensity of phycoerythrin-labeled calibration beads (QuantiBrite, BD Biosciences), calculated as RFIsample/RFISKW6.4 cells × 100.
Percent apoptosis was measured by flow cytometric assessment of caspase-3 activation, as described in “Apoptosis assays.”